AtriCure, Inc. (ATRC): Price and Financial Metrics
ATRC Price/Volume Stats
| Current price | $23.89 | 52-week high | $59.61 |
| Prev. close | $22.71 | 52-week low | $22.27 |
| Day low | $23.18 | Volume | 442,726 |
| Day high | $24.17 | Avg. volume | 678,867 |
| 50-day MA | $30.50 | Dividend yield | N/A |
| 200-day MA | $38.46 | Market Cap | 1.16B |
ATRC Stock Price Chart Interactive Chart >
AtriCure, Inc. (ATRC) Company Bio
Atricure provides atrial fibrillation solutions worldwide. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The company was founded in 2000 and is based in West Chester, Ohio.
Latest ATRC News From Around the Web
Below are the latest news stories about ATRICURE INC that investors may wish to consider to help them evaluate ATRC as an investment opportunity.
Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should KnowThe consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare ConferenceMASON, Ohio, November 15, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference. |
AtriCure Releases 2023 ESG ReportMASON, Ohio, November 14, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023 Environmental, Social and Governance (ESG) Report highlighting the company’s corporate responsibility and sustainability initiatives. |
All You Need to Know About AtriCure (ATRC) Rating Upgrade to BuyAtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
AtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call TranscriptAtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call Transcript November 1, 2023 AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.3. Operator: Good afternoon, and welcome to AtriCure’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end […] |
ATRC Price Returns
| 1-mo | -16.09% |
| 3-mo | -28.86% |
| 6-mo | -29.51% |
| 1-year | -42.28% |
| 3-year | -65.38% |
| 5-year | -15.19% |
| YTD | -33.06% |
| 2023 | -19.58% |
| 2022 | -36.17% |
| 2021 | 24.90% |
| 2020 | 71.24% |
| 2019 | 6.24% |
Continue Researching ATRC
Here are a few links from around the web to help you further your research on AtriCure Inc's stock as an investment opportunity:AtriCure Inc (ATRC) Stock Price | Nasdaq
AtriCure Inc (ATRC) Stock Quote, History and News - Yahoo Finance
AtriCure Inc (ATRC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...